Life Sciences Partners, Ysios Capital, Sunstone Capital and Flerie Invest have led a €32m investment round for Swedish drug developer Oxthera.
In addition to the Dutch, Spanish, Danish and Swedish VCs, the funding round also saw participation from Oxthera's existing backers: French VCs Kurma Partners and Idinvest, Swedish government-backed VC Industrifonden, and Sweden-based investment company Brohuvudet.
Oxthera's capital injection brings the total raised by the biotech business to more than €78m.
The funding will be used to continue development of the company's programme for treatment of primary hyperoxaluria, a potentially fatal disease where sufferers excrete excessive amounts of oxalate in their urine.
Prior to its most recent round, Oxthera had raised in excess of €46m in five rounds over the span of a decade, according to unquote" data.
It first raised SEK 165m from HealthCap and Scandinavian Life Science Ventures in July 2005, followed by a further €16m in 2007, when Industrifonden joined the two existing backers.
Industrifonden led an undisclosed follow-on round in June 2010, with HealthCap joining the Swedish VC in 2012 for an additional €4.67m investment.
In April 2014, HealthCap, Idinvest, Industrifonden and Kurma Partners participated in a €7.5m round for Oxthera.
Oxthera is a Stockholm-based developer of treatments for hyperoxaluria.
The company was founded in 2005 and is developing hyperoxaluria drugs based on live oxalate-consuming bacteria, to prevent kidney damage in sufferers of the disease.
Oxthera – Elisabeth Lindner (CEO).
Catch up on essential features from this past week with our round-up of industry analysis
Gym administration software company will look to expand its US activities following the round
Company will look to expand its technology and personnel resources to match expected growth
Group has undergone several refinancings since Wendel's first investment in 2006